Navigation Links
Codexis Announces Carbon Capture Progress at ARPA-E Summit
Date:2/28/2011

REDWOOD CITY, Calif., Feb. 28, 2011 /PRNewswire/ -- At the ARPA-E Energy Innovation Summit today in Washington, DC, Codexis, Inc. (Nasdaq: CDXS) will announce significant progress towards developing economical, commercial scale technology to reduce carbon dioxide emissions from coal-fired power plants.  The program is supported by an ARPA-E Recovery Act program grant. Coal-fired power plants are major emitters of carbon dioxide, a significant greenhouse gas.

"Current carbon capture technology is inefficient and costly, hindering large scale deployment," said Alan Shaw, Ph.D., President and Chief Executive Officer.  "It can nearly double the cost of electricity produced by a coal-fired power plant, and decrease the amount of total plant electricity output. Using Codexis technology, power plant operators may be able to use more efficient capture methods to decrease the cost of carbon capture.  This, in turn, could lead to wider adoption of this important technology solution."

The data will be presented today in a poster session and tomorrow in a presentation by James Lalonde, Ph.D., Codexis' Vice President of Biochemistry and Engineering Research and Development. Codexis is jointly developing the technology with CO2 Solution, Inc., Quebec, Canada.  

The grant supports development of custom enzymes to decrease energy needed to capture CO2 from coal-fired power plants.  Enzymes developed by Codexis under the grant have been shown to be functional and stable in relatively inexpensive and energy efficient solvents for 24 hours at temperatures up to 75 degrees Celsius.  Use of these solvents with fully developed enzymes is expected to reduce the energy needed to capture CO2 within the plant by 30%.  

This performance is essential to reaching a key goal of the program – using improved technology to reduce the incremental cost of electricity with carbon capture from an 80% increase using presently available technology to no more than a 35% increase.

These reductions are possible through development of customized carbonic anhydrase (CA) enzymes, or biocatalysts.  CA is an enzyme which catalyzes the transfer of carbon dioxide in nature - for example, CA enables carbon dioxide to be released from blood into the lungs during respiration. However, the natural enzyme does not function at the high temperatures and harsh industrial conditions in coal-fired power plant flue gas.  In research being presented this week, enzyme performance has been improved by about 100,000 times over natural forms of the CA enzyme.  For more information on the research programs, visit www.codexis.com and www.co2solution.com.

In May 2010, Codexis was selected to receive up to a $4.7 million ARPA-E Recovery Act program grant from the U.S. Department of Energy for development of innovative technology to remove carbon dioxide from coal-fired power plant emissions.  The grant was one of 37 research projects which the DoE said "could fundamentally change the way the country uses and produces energy."  

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and in carbon capture. Other potential markets include chemicals and water treatment. For more information, see www.codexis.com.

This press release contains forward-looking statements relating to Codexis' research in carbon capture technology.  You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K dated February 10, 2011 including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.Contacts:  Media:  Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771. Investors:  Robert Lawson, robert.lawson@codexis.com, 650-421-8137.
'/>"/>

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Codexis Expands Pharmaceutical Manufacturing Partnerships
5. Codexis, Inc. Announces Pricing of Initial Public Offering
6. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
7. Codexis Names Peter Strumph SVP, Commercial Operations
8. Codexis to Present at the Pacific Crest Technology Leadership Forum
9. Codexis Expands Codex® Panel Product Family at CPhI
10. Codexis to Announce Third Quarter 2010 Financial Results October 28, 2010
11. Codexis to Present at Piper Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):